Reuters logo
Lilly's gastric cancer drug meets late-stage goal
October 15, 2012 / 12:20 PM / in 5 years

Lilly's gastric cancer drug meets late-stage goal

Oct 15 (Reuters) - Eli Lilly and Co said a late-stage study of its experimental gastric cancer drug met its main goal of improving overall survival.

The study, compared the drug ramucirumab to a placebo and the drug was tested as a second-line treatment in patients with cancers that originate in the stomach.

The study, named REGARD, also improved survival without the cancer worsening.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below